Dendritic Cell Vaccine(H. Lee Moffitt Cancer Center and Research Institute)(Dendritic Cell Vaccine(H. Lee Moffitt Cancer Center and Research Institute)) - 药物靶点：HER2 x HER3_在研适应症：HER2阳性乳腺癌，脑膜肿瘤，ER低表达乳腺癌_专利_临床

概要

基本信息

药物类型

治疗性疫苗、树突状细胞疫苗

别名-

靶点

HER2 x HER3

作用机制

HER2调节剂(受体蛋白酪氨酸激酶 erbB-2调节剂)、HER3调节剂(受体酪氨酸蛋白激酶erbB-3调节剂)、免疫刺激剂

治疗领域

肿瘤神经系统疾病皮肤和肌肉骨骼疾病+ [1]

在研适应症

HER2阳性乳腺癌脑膜肿瘤ER低表达乳腺癌+ [2]

非在研适应症-

原研机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

在研机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

5

项与 Dendritic Cell Vaccine(H. Lee Moffitt Cancer Center and Research Institute) 相关的临床试验

NCT06435351 / Recruiting早期临床1期IIT

Precision DC: Personalized Neoantigen Dendritic Cell Vaccine Pilot Trial for High Risk Triple Negative Breast Cancer After Neoadjuvant Therapy

This is a pilot protocol to evaluate the safety, feasibility, and immunogenicity of a personalized breast cancer vaccine based utilizing whole exome sequencing data of a patient's residual breast tumor following neoadjuvant chemotherapy.

开始日期2024-06-12

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

NCT05809752 / Recruiting临床1期IIT

A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) Administered Intrathecally (IT) Primed Against HER2/HER3 in Patients With Leptomeningeal Disease (LMD) From Triple-Negative Breast Cancer (TNBC) or HER2+ Breast Cancer (HER2+BC)

The purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), to find the highest dose of the study treatment that can be given safely to Breast Cancer patients with Leptomeningeal Disease

开始日期2023-08-22

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

[+1]

NCT05504707 / Recruiting临床1期IIT

Phase 1 Dose-Escalation, Dose-Expansion Trial of Intratumoral HER2- and HER3-Primed Dendritic Cells Injections for the Treatment of Early-Stage TNBC and ER Low Positive Breast Cancer (DecipHER)

The purpose of the study is to find out if an investigational vaccine called Dendritic Cell (DC) vaccine given together with standard of care chemotherapy drugs can help people with Triple Negative and HR low positive breast cancer.

开始日期2022-08-26

申办/合作机构

H. Lee Moffitt Cancer Center & Research Institute, Inc.

100 项与 Dendritic Cell Vaccine(H. Lee Moffitt Cancer Center and Research Institute) 相关的临床结果

登录后查看更多信息

100 项与 Dendritic Cell Vaccine(H. Lee Moffitt Cancer Center and Research Institute) 相关的转化医学

登录后查看更多信息

100 项与 Dendritic Cell Vaccine(H. Lee Moffitt Cancer Center and Research Institute) 相关的专利（医药）

登录后查看更多信息

100 项与 Dendritic Cell Vaccine(H. Lee Moffitt Cancer Center and Research Institute) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
HER2阳性乳腺癌	临床1期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-08-22
脑膜肿瘤	临床1期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2023-08-22
ER低表达乳腺癌	临床1期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2022-08-26
HER2 阴性乳腺癌	临床1期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2022-08-26
三阴性乳腺癌	临床1期	美国	H. Lee Moffitt Cancer Center & Research Institute, Inc.	2022-08-26